|Hanley, Michael - AMYLIN PHARMACEUTICALS, INC.|
|Parkes, David - AMYLIN PHARMACEUTICALS, INC.|
|Mcgonicle, Paul - PSYCHOGENICS, INC.|
Submitted to: U.S. Patent and Trademark Office
Publication Type: Other
Publication Acceptance Date: 2/4/2008
Publication Date: 7/1/2010
Citation: Laugero, K.D., Hanley, M.R., Parkes, D.G., Mcgonicle, P. 2010. Neuromedin and FN-38 Peptides for Treating Psychiatric Diseases. Patent Application.
Interpretive Summary: This publication further supports an important relationship between the gut-brain axis, central stress pathways, and psychiatric health, and reports concepts and experimental results supporting the use of metabolic neuromedin peptides for treating neurobehavioral and stress-related diseases and conditions, including schizophrenia; depression, and anxiety.
Technical Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.